Skip to main content
SpringerLink
Log in

Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?

  • Practice Point
  • Published:

From Nature Clinical Practice Cardiovascular Medicine

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Yusuf S et al. for the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345: 494–502

    Article  CAS  Google Scholar 

  2. Sabatine MS et al. for the CLARITY-TIMI 28 Investigators (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352: 1179–1189

    Article  CAS  Google Scholar 

  3. Bhatt DL (2006) Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction? Nat Clin Pract Cardiovasc Med 3: 182–183

    Article  Google Scholar 

  4. Bhatt DL and Topol EJ (2003) Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2: 15–28

    Article  CAS  Google Scholar 

  5. Bhatt DL (2007) Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med 357: 2078–2081

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department of Cardiovascular Medicine, Cleveland Clinic, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA bhattd@ccf.org

Authors and Affiliations

  1. DL Bhatt is an Interventional Cardiologist, Associate Director of the Cardiovascular Coordinating Center, and Associate Professor of Medicine at the Cleveland Clinic in Cleveland, OH, USA.,

    Deepak L Bhatt

Authors
  1. Deepak L Bhatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

DL Bhatt has received research funding (directly to the Cleveland Clinic) from Bristol-Myers Squibb, Eisai, Ethicon, Heartscape Technologies, Sanofi-Aventis, and The Medicines Company. He has received payments for Speaker's Bureau appointments from Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company. He has received honoraria from AstraZeneca, Bristol-Myers Squibb, Centocor, Eisai, Eli Lilly, GlaxoSmithKline, Millennium Pharmaceuticals, ParinGenix, PDL BioPharma, Sanofi-Aventis, Schering Plough, The Medicines Company, and TNS Healthcare. He has also acted as a Consultant or Advisory Board member for Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardax Pharmaceuticals, Centocor, Cogentus Pharmaceuticals, Daiichi-Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Medtronic, Millennium Pharmaceuticals, Molecular Insight Pharmaceuticals, Ortho-McNeil Pharmaceutical, Otsuka, ParinGenix, PDL BioPharma, Philips Medical, Portola Pharmaceuticals, Sanofi-Aventis, Schering Plough, Scios, The Medicines Company, TNS Healthcare, and Vertex Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhatt, D. Is prasugrel superior to clopidogrel for patients with acute coronary syndromes undergoing PCI?. Nat Rev Cardiol 5, 252–253 (2008). https://doi.org/10.1038/ncpcardio1164

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1164

  • Springer Nature Limited

This article is cited by

Search

Navigation